Skip to main content
Premium Trial:

Request an Annual Quote

DiscoveRx Acquires BioSeek

NEW YORK (GenomeWeb News) – DiscoveRx today said that it has acquired BioSeek, maker of the BioMAP platform of cell-based disease models for drug screening.

Financial terms of the deal were not disclosed.

"The integration of BioSeek provides two new capabilities to DiscoveRx Corporation," Pyare Khanna, president and CEO of Fremont, Calif.-based DiscoveRx, said in a statement. "Expertise in primary cell disease models as well as a highly differentiated compound characterization service. These new capabilities further strengthen our position as a premier drug discovery solution provider that develops and commercializes high-value products and specialized services."

BioSeek formerly was part of Asterand, a Detroit-based provider of human tissue and human tissue-based research tools.

The South San Francisco, Calif.-based firm recently won an extension for a contract from the Environmental Protection Agency to participate in the ToxCast program. Under the new, five-year contract, BioSeek will receive up to $46,770,000 to test up to 60,000 samples using the BioMAP platform.

Privately held DiscoveRx offers cell-based assay platforms for drug discovery research.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.